Semiglutide Pen 10mg
Semaglutide is a GLP-1 receptor agonist used primarily to treat type 2 diabetes and support weight management. The Semaglutide 10mg pen typically refers to a multi-dose injection pen containing 10mg of semaglutide in total, which is administered subcutaneously (under the skin). ⚕️ Key Details: • Brand Names: Ozempic, Wegovy (depending on dosage and indication) • Generic Name: Semaglutide • Form: Pre-filled injection pen • Strength: 10mg total per pen (usually delivering multiple doses) • Route of Administration: Subcutaneous injection (abdomen, thigh, or upper arm) • Use: • Improves blood sugar control in adults with type 2 diabetes • Aids in weight loss when used in higher doses (with diet and exercise) 💉 Pen Format: • The 10mg pen is often used in titration to reach maintenance doses like 1.0 mg or 2.4 mg weekly, depending on the indication (e.g., diabetes vs obesity). • Depending on the pen design, it may allow multiple weekly doses (e.g., 1 mg/week = 10 weeks of use per pen). ⏱️ Dosing Schedule: • Typically administered once weekly on the same day each week • Initial dose often starts lower (e.g., 0.25 mg) and is gradually increased to minimize side effects ⚠️ Common Side Effects: • Nausea • Vomiting • Diarrhea or constipation • Reduced appetite • Headache 🛑 Warnings: • Not for use in type 1 diabetes or diabetic ketoacidosis • Risk of thyroid C-cell tumors (seen in animal studies) • Should not be combined with other GLP-1 receptor agonists Let me know if you need specific brand details (e.g., Ozempic vs Wegovy), pricing, or usage instructions.
£140.00
Mounjaro Pen 10mg
Mounjaro 10 mg KwikPen: ⸻ 🖊️ What It Is • Active Ingredient: Tirzepatide – a dual-action GIP + GLP‑1 receptor agonist. This means it mimics two natural gut hormones to promote insulin release, reduce blood sugar, and suppress appetite . • Brand: Mounjaro (by Eli Lilly), approved as an injectable for type 2 diabetes, and authorized for weight management in the UK and US . ⸻ 💉 Pen Details • Strength: Each dose delivers 10 mg of tirzepatide in a 0.6 mL injection. • Pen Content: The refillable pen holds 40 mg total in 2.4 mL, providing 4 doses per pen . • Form: Clear to slightly yellow solution in a multi-dose KwikPen—no needle handling or mixing required . ⸻ 🕐 Dosage & Administration • Frequency: Once-weekly subcutaneous injection (abdomen, thigh, upper arm) . • Start: Typically begins at 2.5 mg/week and increases every 4 weeks, eventually reaching the 10 mg maintenance dose . • Missed Dose: Can be taken within 4 days of missed dose; after that, resume regular schedule—no double dosing . ⸻ 🧪 Mechanism of Action • Dual Incretin Effect: Stimulates insulin secretion and improves insulin sensitivity by activating both GIP and GLP‑1 receptors—resulting in stronger blood sugar control and often greater weight loss than GLP‑1–only medications . • Weight Loss Evidence: Clinical trials show significant reductions in HbA1c and body weight—SURPASS‑2 reported A1C drops of 2.0–2.3% and weight loss of 7.7–11.4 kg (17–25 lb) with the 10 mg dose . ⸻ ⚠️ Safety & Side Effects • Common Side Effects: • Gastrointestinal – nausea, vomiting, diarrhea, constipation, indigestion  • Warnings: • Not for type 1 diabetes or those with a history of pancreatitis. • Contraindicated in people with medullary thyroid carcinoma or multiple endocrine neoplasia type 2  . ⸻ 🔄 Storage & Handling • Before Use: Store in fridge (2–8 °C); protect from light. Do not freeze . • Portability: After removal from refrigeration, pen stable at up to 30 °C for 21 days . • Discard: Replace pen after 4 full doses; follow local disposal guidelines . ⸻ 🎯 Summary • Indication: Weekly injectable for type 2 diabetes, with off-label use for weight loss. • Format: Multi-dose pen delivering 10 mg per injection (0.6 mL), with 4 doses per pen. • Mechanism: Dual GIP+GLP‑1 action enhances glycemic control and appetite suppression. • Benefits: Significant HbA1c lowering and body weight reduction. • Side Effects: Mainly GI issues; has thyroid, pancreatitis, and hypoglycemia warnings.
£140.00
